Clinical efficacy of icotinib in patients with advanced nonsquamous non-small cell lung cancer with unknown EGFR mutation status that failed to respond to second-line chemotherapy
نویسندگان
چکیده
منابع مشابه
Clinical efficacy of icotinib in lung cancer patients with different EGFR mutation status: a meta-analysis
Icotinib is a novel and the third listed epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), which exerts a good anti-tumor efficacy on non-small cell lung cancer (NSCLC). The efficacy of EGFR-TKIs has been shown to be associated with the EGFR mutation status, especially exon 19 deletion (19Del) and exon 21 L858R mutation. Therefore, a meta-analysis was performed to assess ...
متن کاملEfficacy of first-line chemotherapy affects the second-line setting response in patients with advanced non-small cell lung cancer.
BACKGROUND Chemotherapy is the mainstay of treatment for the majority of patients with advanced non- small cell lung cancer (NSCLC) without driver mutations and many receive therapies beyond first-line. Second- line chemotherapy has been disappointing both in terms of response rate and survival and we know relatively little about the prognostic factors. MATERIALS AND METHODS One thousand and ...
متن کاملEfficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer.
OBJECTIVE To evaluate the efficacy and safety of icotinib hydrochloride in patients with advanced non-small cell lung cancer (NSCLC). METHODS A total of 89 patients with stage IIIB or IV NSCLC received icotinib at a dose of 125 mg administered 3 times a day. Icotinib treatment was continued until disease progression or development of unacceptable toxicity. RESULTS A total of 89 patients wer...
متن کاملCorrelation between EGFR mutation status and response to first-line platinum-based chemotherapy in patients with advanced non-small cell lung cancer
BACKGROUND The purpose of this research was to investigate the relationship between epidermal growth factor receptor (EGFR) mutations and the response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). METHODS A total of 266 patients with stage IIIB or IV NSCLC who received platinum-based doublet therapies as first-line chemotherapy were investigated retr...
متن کاملSecond-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer.
it might be difficult to obtain further specimens or the patient might dislike the idea of re-biopsy. Currently, egfr tkis in wild-type nsclc tumours—that is, in the second line—demonstrate the same modest efficacy as chemotherapy agents do (response rate, progression-free survival, median overall survival) 3–6, but the hope is to eventually replace such treatments with more specific, personali...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Translational Medicine
سال: 2018
ISSN: 2305-5839,2305-5847
DOI: 10.21037/atm.2018.09.54